XBP1 is considered as a biomarker of poor clinical outcomes in patients with pulmonary adenocarcinoma (Kwon et al., 2018), breast cancers (Chen et al., 2014), and multiple myeloma (Bagratuni et al., 2010). This evidence concerns the gene XBP1 and AL amyloidosis.